CSBR Relative Valuation
CSBR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CSBR is overvalued; if below, it's undervalued.
Historical Valuation
Champions Oncology Inc (CSBR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 41.19. The fair price of Champions Oncology Inc (CSBR) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：6.04
Fair
40.67
PE
1Y
3Y
5Y
Trailing
Forward
37.18
EV/EBITDA
Champions Oncology Inc. (CSBR) has a current EV/EBITDA of 37.18. The 5-year average EV/EBITDA is 20.31. The thresholds are as follows: Strongly Undervalued below -77.24, Undervalued between -77.24 and -28.47, Fairly Valued between 69.08 and -28.47, Overvalued between 69.08 and 117.85, and Strongly Overvalued above 117.85. The current Forward EV/EBITDA of 37.18 falls within the Historic Trend Line -Fairly Valued range.
-62.38
EV/EBIT
Champions Oncology Inc. (CSBR) has a current EV/EBIT of -62.38. The 5-year average EV/EBIT is 21.85. The thresholds are as follows: Strongly Undervalued below -256.64, Undervalued between -256.64 and -117.39, Fairly Valued between 161.10 and -117.39, Overvalued between 161.10 and 300.34, and Strongly Overvalued above 300.34. The current Forward EV/EBIT of -62.38 falls within the Historic Trend Line -Fairly Valued range.
1.34
PS
Champions Oncology Inc. (CSBR) has a current PS of 1.34. The 5-year average PS is 1.85. The thresholds are as follows: Strongly Undervalued below 0.45, Undervalued between 0.45 and 1.15, Fairly Valued between 2.56 and 1.15, Overvalued between 2.56 and 3.26, and Strongly Overvalued above 3.26. The current Forward PS of 1.34 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Champions Oncology Inc. (CSBR) has a current P/OCF of 0.00. The 5-year average P/OCF is 2.32. The thresholds are as follows: Strongly Undervalued below -17.52, Undervalued between -17.52 and -7.60, Fairly Valued between 12.24 and -7.60, Overvalued between 12.24 and 22.16, and Strongly Overvalued above 22.16. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-82.47
P/FCF
Champions Oncology Inc. (CSBR) has a current P/FCF of -82.47. The 5-year average P/FCF is 51.69. The thresholds are as follows: Strongly Undervalued below -303.35, Undervalued between -303.35 and -125.83, Fairly Valued between 229.21 and -125.83, Overvalued between 229.21 and 406.72, and Strongly Overvalued above 406.72. The current Forward P/FCF of -82.47 falls within the Historic Trend Line -Fairly Valued range.
Champions Oncology Inc (CSBR) has a current Price-to-Book (P/B) ratio of 23.54. Compared to its 3-year average P/B ratio of 65.87 , the current P/B ratio is approximately -64.26% higher. Relative to its 5-year average P/B ratio of 45.45, the current P/B ratio is about -48.19% higher. Champions Oncology Inc (CSBR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.08%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.67% , the current FCF yield is about -100.00% lower.
23.98
P/B
Median3y
65.87
Median5y
45.45
8.77
FCF Yield
Median3y
-1.08
Median5y
-0.67
Competitors Valuation Multiple
The average P/S ratio for CSBR's competitors is 0.00, providing a benchmark for relative valuation. Champions Oncology Inc Corp (CSBR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -0.47%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CSBR decreased by 28.82% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 13.79 to 28.59.
The secondary factor is the Revenue Growth, contributed -0.47%to the performance.
Overall, the performance of CSBR in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Champions Oncology Inc (CSBR) currently overvalued or undervalued?
What is Champions Oncology Inc (CSBR) fair value?
How does CSBR's valuation metrics compare to the industry average?
What is the current P/B ratio for Champions Oncology Inc (CSBR) as of Dec 05 2025?
What is the current FCF Yield for Champions Oncology Inc (CSBR) as of Dec 05 2025?
What is the current Forward P/E ratio for Champions Oncology Inc (CSBR) as of Dec 05 2025?